Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
WTP, Probably the fear of causing another drop In the SP. IMO
Excellent post @konara at 10:51.
So Scancell could likely still be in closed period as you say, and yes I wonder how many sold on that RNS?
Btw why have they not RNS'd a correction though?
Moonparty -
RG has already exercised one tranche so this is the second. I think he has approx. 600k left.
It was always obviously Goodfellow (or someone else no longer involves) and will clearly have been driven by tax-planning, to “take the taxable gain” at a time when the share price was low (and so the gain and tax on it will also be low). There will doubtless be another round very soon for 24/25.
Not impressed by an error in the published details - there is no excuse for sloppy errors re the exercise price!
Thanks jb1, so it is seems likely Richard Goodfellow has sold a million recently, unless he exercised them for a different reason than to raise money (only thing I can think of is to gift the shares to someone else?).
Would explain a lot, and as he is now retired, understandable he wants to cash some in. Reassuring it was only a million as he has a lot more options than this I think.
Johnny,
Thanks for spotting this in the first place and then finding the answer - great research.
That's a pretty epic mistake to make!
Not only is it 50% less revenue generated from the sale of the shares, but a number of people inferred from the exercise of the option that Scancell weren't in a close period. I could well imagine a number of sells went through on that basis - if I remember correctly the price dropped that day.
JB1 - thanks for sharing with the BB. Much appreciated.
On 19 March’24, I posted that Scancell Holdings had made a filing of a “Statement of capital following allotment of shares” at Companies House that day. It showed that 1,000,000 shares have been allotted at a price of 10 pence each:-
https://find-and-update.company-information.service.gov.uk/company/06564638/filing-history
It did not make sense because no share options for 10 pence could be found in Scancell’s accounts. I raised the question with Scancell and they have emailed the following response:-
“I apologise that your email has not been responded to earlier.
Unfortunately, there was an error on the SH01 form filed at Companies House and the allotment price shown should have been £0.045 not £0.1. An amended SH01 has been submitted to Companies House and their site will be updated in due course.
The allotment related to the exercise of share options, and I’ve attached a copy of the relevant RNS.”
This is the RNS they attached:-
https://www.lse.co.uk/rns/SCLP/block-listing-application-to-aim-i1jcwgms4055mk9.html
So, it was Richard Goodfellow exercising another 1,000,000 of his 4.5 pence options.
'but' not 'nut' . . .
On 'PoG or PoS' thread over there, an interesting discussion between Inan and Bermuda about the timing of possible interest arising from the SCIB1 / iSCIB1+ trials.
To expand on previous comment, the thread I politely call PoG is actually, "Pot of Gold OR Pot of S*** "
Firmly the former in my view of course - nut not just yet. GLA
Thanks for posting EE. Very encouraging to see someone has picked up on Scancell’s presentation at AACR….was beginning to be a touch concerned at the complete lack of coverage.
Https://www.cancertherapyadvisor.com/reports/scib1-vaccine-nivo-ipi-melanoma/
….interesting read…..
The below 10p share price is frustrating when we know that the science is gaining traction.
The clinical trials must be consuming 10’s of thousands a week and be creating vast amounts of admin to ensure Scancell conform with the all the trial protocols and legislation.
This is a very expensive business and the only way to see a return on that investment is for the trial data to be converted into MHRA or FDA approvals. Even then it has to be good enough to convince the medical professionals to adopt and recommend to their patients.
The recent AACR was a great place to get the message out that this treatment is working extremely well and has a high probability that it will be approved and adopted in the coming years.
SCIB1 plus the two checkpoints is working in an area of Melanoma cancer that so far has no treatment. So we can be excited by the fact that patients lives are being extended where previously there was no hope. We also have to understand that at the moment we only know the data for 13 patients. As our Chairman pointed out, we need positive data in a minimum trial sample of 40 patients. At that point it becomes clinically / statistically significant.
We cannot be very far from having that kind of data. Scancell’s target is to have that level of patients enrolled by the end of June and the scan data by the end of September. It could be a lot earlier if the 85% ORR is maintained.
@Burble Any suggestions?
Dracula, I've slowly been averaging down over the years with a drip feed of purchases whenever I've had some spare cash. Still slightly underwater but it's not a crazy amount that it needs to climb to get back into a small profit. I'm hoping to hold out for when it does rise, but I've stopped making any major purchases as I feel there are other opportunities to invest in other companies where the returns will be greater/quicker than locking more money up here.
The uncomfortable and very annoying fact, however, is that the share price is basically where is was in 2020, which is also roughly the same as Redmile’s average in-price and, more irritatingly, my own.
Other than the recent small fund raise since, I can see absolutely no reason why the share price is a mere fraction of “derisory” - other than the drag of being listed in London instead of the more vibrant and accurate NASDAQ.
The valuation gap needs to be closed as a matter of urgency……
Burble I hope you got in at the 4P/10P range not at the 40P. Commiserations If you did at the 40P.. Isn't It near unbelievable that with ALL the progress Sclp have made In all the different Trials that Investors/Pharmas/11s don't see that SP value today after All that time and progress?. IMO.
I agree C11 in 2020 was indeed interesting especially Redmile were also early investors of BioNTech let’s hope magic rubs off in all directions for patients and share price
I also believe references to 10+ years etc are a little misleading in respect of what has been achieved by Lindy and her team. The Company wasn’t really well funded until Redmile came along in late 2020.
TF, Burble,
Like you, I have been invested for many years (since July 2012)
However I disagree with "we're waiting for something transformative to happen" statement.
There have been a number of transformative events, just that none of them have resulted in a permanent transformation in the share price.
Thanks Burble. I had wondered if you were the long lamented Puritas who was one of many other Posters missing now!
Likewise - "nearly 13 years it’s been and still waiting for something transformative to happen." GLA
The collaboration agreement with BioNTech 2019
Scancell to collaborate with BioNTech
Scancell to collaborate with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer
Agreement expands potential therapeutic utility of Moditope® to adoptive T cell therapy
Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has entered into a research collaboration with BioNTech for the potential development of innovative, T cell receptor based therapeutics for the treatment of cancer. This research collaboration combines Scancell’s Moditope® immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.
Moditope® represents a completely new class of potent and selective immunotherapy agents which could have a profound effect on the way that cancer immunotherapies are developed. It acts by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes which overcome self-tolerance and destroy tumour cells. The technology overcomes the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors, thereby allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Under the terms of the agreement, Scancell and BioNTech will enter into an initial research collaboration to discover and characterise T cell receptors specific for citrullinated epitopes from vimentin and enolase. These epitopes form the basis of Scancell’s first Moditope® development candidate, Modi-1. Upon completion of these studies, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.
A reminder of the research agreement with BioNTech
https://www.scancell.co.uk/scancell-to-collaborate-with-biontech
TF
Thanks for your post .. I found this was posted by Scancell in their LinkedIn page . And has had 64 likes
I find it odd again mentioning Biontech ?
I also posted A video of prof Sarah Danson ( an author of the abstract ) from the focus melanoma conference . Sponsors by Scancell . Ther was a whole slide seditious The uk government investment / partnership with Biontech and Moderna ?
Wonder where the research collaboration with Scancell and BioNTech agreed in 2019 !
Seems odd BioNTech mentioned in Rns post LinkedIn page and presentation at Mellanoma conference .
I have cut and paste from Scancell LinkedIn page
ICYMI, Scancell Ltd CEO Lindy Durrant presented data at American Association for Cancer Research on its open-label Phase 2 SCOPE trial investigating its cancer vaccine, SCIB1 in advanced melanoma, as part of the #AACR ‘Cancer Vaccines: Ready for Prime Time?’ clinical trials symposium.
The session covered progress from a number of other innovative clinical stage cancer vaccines including follow up data from the BioNTech mRNA vaccine, which reported T cells could still be detected at the three-year follow-up point. This is highly encouraging for the cancer vaccine space, particularly as SCIB1 has demonstrated an 85% response rate among 13 first-line advanced melanoma patients.
🔎 Learn more about SCOPE: https://lnkd.in/eivcrTxX
#cancervaccine #melanoma #AACR24 #immunooncology #immunotherapy